All In Biotech

Drug Trial Radar · NCT03161093

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Last checked: Nov 19, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,307

Actual

Start

Aug 17, 2017

Primary completion

Sep 9, 2019

Study completion Aug 27, 2021

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Teva Pharmaceutical Industries, Ltd.
First posted
May 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of fasinumab compared with placebo, when administered for up to 16 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip. The secondary objectives of the study are: 1. To evaluate the efficacy of fasinumab compared with naproxen, when administered for up to 16 weeks in patients with pain due to OA of the knee or hip 2. To evaluate the efficacy of fasinumab compared with placebo, when administered for up to 44 weeks in patients with pain due to OA of the knee or hip 3. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 16 weeks in patients with pain due to OA of the knee or hip 4. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 52 weeks in patients with pain due to OA of the knee or hip 5. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 104 weeks in patients with pain due to OA of the knee or hip 6. To evaluate the pharmacokinetic (PK) profile of fasinumab administered to patients with pain due to OA of the knee or hip for up to 52 weeks 7. To evaluate the PK profile of fasimumab administered to patients with pain due to OA of the knee or hip for up to 104 weeks 8. To evaluate the immunogenicity of fasinumab administered to patients with pain due to OA of the knee or hip for up to 52 weeks 9. To evaluate the immunogenicity of fasinumab administered to patients with pain due to OA of the knee or hip for up to 104 weeks 10. To evaluate the efficacy of fasinumab compared with naproxen, when administered for up to 44 weeks in patients with pain due to OA of the knee or hip

Conditions

  • Osteoarthritis, Knee
  • Osteoarthritis, Hip

Interventions

  • FasinumabDrug

    Solution for injection in pre-filled syringe

  • NaproxenDrug

    Pharmaceutical form: Capsule

  • Fasinumab-matching placeboDrug

    Solution for injection in pre-filled syringe

  • Naproxen-matching placeboDrug

    Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q4W Compared With That of Participants Treated With PlaceboTime frame: Baseline to Week 16
  2. Change in the WOMAC Physical Function Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg Q4W Compared With That of Participants Treated With PlaceboTime frame: Baseline to Week 16
  3. Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q8W Compared With That of Participants Treated With PlaceboTime frame: Baseline to Week 16
  4. Change in the WOMAC Physical Function Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg Q8W Compared With That of Participants Treated With PlaceboTime frame: Baseline to Week 16

Locations

139 sites in 12 countries. Site status is shown where the registry gives one.

  • Arizona Arthritis & Rheumatology Research, PLLC

    Mesa, Arizona

  • Arizona Research Center

    Phoenix, Arizona

  • Tucson Orthopaedic Research Center

    Tucson, Arizona

  • Baptist Health Center for Clinical Research

    Little Rock, Arkansas

  • Medvin Clinical Research

    Covina, California

  • TriWest Research Associates, LLC

    El Cajon, California

  • BioSolutions Clinical Research

    La Mesa, California

  • Pacific Arthritis Care Center

    Los Angeles, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Artemis Clinical Research

    San Marcos, California

  • Lynn Institute of Denver

    Aurora, Colorado

  • Lynn Institute of the Rockies

    Colorado Springs, Colorado

  • Panorama Orthopedics & Spine Center

    Golden, Colorado

  • Arthritis and Rheumatic Disease Specialties

    Aventura, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Sensible Healthcare

    Ocoee, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Jewett Orthopaedic Clinic

    Orlando, Florida

  • Lovelace Scientific Resources

    Venice, Florida

  • Meridian Clinical Research

    Savannah, Georgia

  • Advanced Clinical Research

    Meridian, Idaho

  • Medex Healthcare Research, Inc.

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • Healthcare Research Network II, LLC

    Flossmoor, Illinois

  • Integrated Clinical Trial Services, Inc.

    West Des Moines, Iowa

  • Klein & Associates, MD PA

    Cumberland, Maryland

  • Klein & Associates, MD, PA

    Hagerstown, Maryland

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts

  • The Center for Pharmaceutical Research

    Kansas City, Missouri

  • Medex Healthcare Research, Inc.

    St Louis, Missouri

  • Sundance Clinical Research, LLC

    St Louis, Missouri

  • Physician Research Collaboration, LLC

    Lincoln, Nebraska

  • Lovelace Scientific Resources, Inc.

    Albuquerque, New Mexico

  • United Medical Associates

    Binghamton, New York

  • Regional Clinical Research, Inc.

    Endwell, New York

  • Medex Healthcare Research

    New York, New York

  • Buffalo Rheumatology and Medicine, PLLC

    Orchard Park, New York

  • Orchard Park Family Practice

    Orchard Park, New York

Showing 40 of 139 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.